AbbVie, BMS Partner on Cancer Clinical Collaboration
Monday, July 25, 2016
Source: Gen News
AbbVie and Bristol-Myers Squibb (BMS) said today they will launch an oncology clinical collaboration to assess two combination treatments for relapsed, extensive-stage, small-cell lung cancer (SCLC).
The value of the Phase I/II clinical collaboration was not disclosed.
The companies will study AbbVie's investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituzumab tesirine) in combination with BMS’ marketed immuno-oncology treatment Opdivo® (nivolumab), as well as the combination of Rova-T and an Opdivo + Yervoy® (ipilimumab) immuno-oncology regimen.